Pozen (Nasdaq: POZN) has partnered with giants to develop drugs. Now that it is developing its own products the company is beefing up efforts to bring those to market.
On Tuesday, Pozen took the latest step, hiring Clint Burris as vice president for customer development.
A veteran life sciences executive, Burrus will be tasked to prepare the way for Pozen’s combination pain reliver under development called PA32540. It is in Phase 3 clinical trials, and Pozen hopes to submit a New Drug Application to the FDA next year.
Pozen says it has a portfolio of products under development that include aspirin and additional ingredients that limit gastrointestinal damage that can be caused by aspiring.
“Mr. Burrus is an exciting addition to the POZEN team,” said Liz Cermak, executive vice president and Chief Commercial Officer of Pozen, in a statement. “His extensive experience with managed markets, government, and trade customers will help us develop strategies in these areas that are critical to the success of the PA family of product candidates.”
Cermak is responsible for development and implementation of Pozen’s future products. She also manages Pozen’s business development and strategic alliances Cermak joined the firm in September 2009 from Johnson & Johnson.
Burrus most recently served as an executive vice president at King Pharmaceuticals.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
